Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
412.40M | 429.63M | 408.55M | 333.95M | 265.99M | 274.72M | Gross Profit |
190.40M | 278.72M | 140.37M | 101.66M | 76.44M | 171.59M | EBIT |
33.01M | 46.28M | 49.13M | 31.81M | 20.56M | 16.82M | EBITDA |
61.51M | 87.80M | 87.01M | 66.13M | 50.77M | 43.92M | Net Income Common Stockholders |
19.94M | 31.31M | 31.26M | 18.73M | 9.97M | 9.30M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
29.35M | 65.60M | 76.00M | 84.29M | 73.32M | 31.09M | Total Assets |
170.10M | 450.97M | 420.86M | 403.40M | 356.29M | 287.26M | Total Debt |
19.57M | 205.26M | 166.38M | 173.20M | 180.77M | 129.42M | Net Debt |
-9.78M | 139.67M | 90.38M | 88.91M | 107.45M | 98.33M | Total Liabilities |
108.37M | 346.17M | 326.13M | 320.02M | 289.65M | 228.12M | Stockholders Equity |
60.92M | 102.85M | 92.97M | 81.77M | 64.78M | 57.05M |
Cash Flow | Free Cash Flow | ||||
33.52M | 27.63M | 53.03M | 70.18M | 51.91M | 42.63M | Operating Cash Flow |
47.64M | 51.13M | 63.04M | 80.69M | 57.88M | 51.26M | Investing Cash Flow |
-19.14M | -27.46M | -20.83M | -10.36M | -19.94M | -7.98M | Financing Cash Flow |
-38.52M | -34.16M | -51.23M | -60.49M | 4.88M | -26.27M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | €400.17M | 25.63 | 15.82% | 6.33% | -3.64% | -50.51% | |
62 Neutral | $6.82B | 11.05 | 2.80% | 4.32% | 2.67% | -24.92% | |
$278.82B | 56.18 | 28.67% | 3.88% | ― | ― | ||
€21.43B | 16.53 | 2.57% | 1.84% | ― | ― | ||
€21.16B | 18.68 | 7.52% | 3.48% | ― | ― | ||
€2.44B | 9.04 | 9.58% | 3.60% | ― | ― |
Roche Bobois SA reported its 2024 annual results, showing resilience despite a challenging market environment. The company saw a slight revenue decline of 3.6% to 414 million euros, with EBITDA aligning with expectations at 74.4 million euros. The company maintained strong financial health with significant cash flows and plans to propose a dividend of 1.25 euros per share. Strategic investments in expanding owned stores in key regions like the US and China are expected to support future growth, with a positive outlook for 2025 revenue and EBITDA.
Roche Bobois SA announced a share buyback program, authorized by the general meeting in June 2024, with transactions executed between February 10 and 14, 2025. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting its strong financial position and commitment to maintaining its market presence.